The 5 bullish analyst ratings for Cormedix in the last quarter indicate a positive outlook for the stock. The average 12-month price target of $14.8, despite being down 7.5% from the previous average, still suggests potential upside for the stock. This information is important for investors as it reflects the analysts' expectations for the company's future performance.